Inpharma 1321 - 19 Jan 2002

■ The non-peptidic protease inhibitor tipranavir*

has shown promising results in patients with HIVinfection whose first protease inhibitor-containingregimen was failing, according to a study presented atthe 41st Interscience Conference on Antimicrobialsand Chemotherapy. In this open-label trial, 63 patientswere randomised to receive twice-daily treatment withtipranavir 1250mg plus ritonavir 100mg (TPV1250group; n = 21), or tipranavir 500 mg plus ritonavir100mg (TPV500 group; 21), or saquinavir 400mg plusritonavir 400mg (SQV group). All patients alsoreceived two new nucleoside reverse transcriptaseinhibitors. Preliminary analysis after 16 weeks showedthat HIV RNA levels were < 50 copies/ml in 35% ofpatients in the TPV1250 group, 22% of the TPV500group and 30% of the SQV group. The most commonadverse events were mild gastrointestinal effects.* Boehringer Ingelheim; phase II

Boehringer Ingelheim Pharmaceuticals Inc. Boehringer Ingelheim presentslate-breaking data on tipranavir, first non-peptidic protease inhibitor (NPPI).Media Release : [2 pages], 18 Dec 2001. Available from: URL: http://www.boehringer-ingelheim.com 800876982

1

Inpharma 19 Jan 2002 No. 13211173-8324/10/1321-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved